Central serous chorioretinopathy and drug toxicity
This lesson covers two kinds of macular disease that a doctor can cause or relieve with a prescription pad. Central serous chorioretinopathy is a blister of fluid under the macula, strongly linked to corticosteroids. Hydroxychloroquine retinopathy is a slow, irreversible poisoning of the macula that the Royal College of Ophthalmologists asks us to look for with annual imaging. Chloroquine, tamoxifen and vigabatrin are covered in brief.
What central serous chorioretinopathy is
The retinal pigment epithelium (RPE) forms the outer blood-retinal barrier. Its cells are joined by tight junctions and they pump fluid out of the subretinal space towards the choroid, which keeps the photoreceptors applied to the RPE. In central serous chorioretinopathy (CSC) this arrangement fails at the macula and clear fluid collects between the photoreceptors and the RPE: a serous detachment of the neurosensory retina.
3D atlasIn CSC, fluid from a congested choroid passes through a defect in the RPE and lifts the photoreceptors.The primary fault is thought to lie in the choroid. Its vessels are dilated and abnormally permeable, and the choroid is thick (the 'pachychoroid' appearance). Pressure from the congested choroid pushes fluid against the RPE, which lifts in small blisters (pigment epithelial detachments) and then gives way at one or more points, letting fluid through.
CSC is a disease of working-age adults, with a mean age in the forties, and men are affected about six times as often as women. The strongest association is with corticosteroids, by any route: tablets, inhalers, nasal sprays, joint injections and skin creams have all been implicated, as has the body's own cortisol in Cushing syndrome. Other associations are pregnancy, psychological stress and 'type A' personality (though the evidence for these is weaker), obstructive sleep apnoea and Helicobacter pylori infection.
Symptoms, signs and imaging
The patient notices blurring and a dim grey patch in the centre of vision in one eye. Each symptom can be explained by the fluid. The retina is lifted forwards, so the eye behaves as if it were shorter and acuity may improve with a weak plus lens (a hyperopic shift). The photoreceptors over the blister are spread apart, so an image falls on fewer of them and objects look smaller (micropsia). Uneven lifting distorts straight lines (metamorphopsia). Colours look washed out and contrast is reduced. Acuity is often only mildly reduced.
On examination there is a round, shallow, clear elevation at the macula. OCT makes the diagnosis: a dome of dark (optically empty) fluid under the neurosensory retina, often with a small pigment epithelial detachment and a thickened choroid. There is no blood, which helps to separate CSC from wet macular degeneration.
Fluorescein angiography shows the leak through the RPE. The commoner pattern is the ink blot, a dot that slowly enlarges. The classic pattern, seen in a minority, is the smokestack: dye enters the blister, rises and spreads sideways like smoke from a chimney. Indocyanine green angiography, which images the choroid, shows patches of choroidal hyperpermeability wider than the fluorescein leak.
Natural history and treatment
Acute CSC usually gets better without treatment. The fluid resolves within about 3 to 4 months in most patients, with good recovery of acuity, though some loss of contrast and colour may remain. It recurs in roughly a third to a half of patients. The standard approach is therefore to stop steroids if possible, address stress and sleep apnoea, and observe for 3 to 4 months.
Fluid that persists beyond that is called chronic CSC. Long-standing fluid damages photoreceptors and RPE and can permanently reduce vision, and a few eyes develop choroidal neovascularisation. Chronic or recurrent disease is treated with photodynamic therapy: verteporfin, a light-activated dye, is given intravenously at half the usual dose and activated with a low-energy laser over the leaking choroid, which reduces its permeability. Focal laser to a leak well away from the fovea is an older alternative.
Hydroxychloroquine retinopathy
Hydroxychloroquine is used long term in rheumatoid arthritis, lupus and other connective tissue diseases. It binds to melanin and accumulates in the RPE, where it stays for a long time. There it damages lysosomes and impairs the RPE's digestion of shed photoreceptor outer segments. The RPE and then the photoreceptors degenerate.
The damage classically forms a ring around the fovea, sparing the very centre until late. Early disease has no symptoms. Later the patient notices difficulty reading from a ring-shaped scotoma near fixation. The end stage is a bull's eye maculopathy: a ring of pale, atrophic RPE around a darker central island. In patients of Asian heritage the damage is often further out, near the vascular arcades, so tests confined to the central macula can miss it.
Retinopathy is irreversible and can continue to progress after the drug is stopped, because the drug clears slowly. The purpose of monitoring is to detect damage on imaging before the patient loses central vision. With modern imaging, about 7.5% of people who have taken hydroxychloroquine for more than five years show retinopathy, and the proportion rises with dose and duration.
Imaging signs come before symptoms. OCT shows loss of the photoreceptor ellipsoid zone around the fovea with the centre preserved, a shape called the flying saucer sign. Fundus autofluorescence, which maps lipofuscin in the RPE, shows a ring of abnormal signal around the fovea.
The RCOphth monitoring recommendations
The Royal College of Ophthalmologists revised its guidance in 2020. The main points are below.
- No baseline examination. Baseline testing of new starters is no longer recommended, because audits showed it almost never changed management.
- Annual monitoring after 5 years of hydroxychloroquine, continued for as long as the drug is taken.
- Earlier monitoring, from one year, if there are additional risk factors: a dose above 5 mg/kg per day, an eGFR below 60 ml/min/1.73 m2 (the drug is cleared by the kidney), or concurrent tamoxifen.
- Chloroquine is more toxic to the retina, so everyone taking it is monitored annually after 1 year.
- Tests: spectral-domain OCT and fundus autofluorescence, widefield if available, for everyone. Automated visual fields (10-2 for central, 30-2 for more peripheral defects) are done only if imaging is abnormal. Multifocal electroretinography is used when imaging is abnormal but fields are normal.
- Definite toxicity means typical changes on two tests. The ophthalmologist then recommends stopping, but the decision is made by the prescribing doctor with the patient, because the drug may be controlling serious disease. Possible toxicity means one abnormal test: the drug is continued and the patient is tested further.
A dose of 400 mg a day exceeds 5 mg/kg in anyone lighter than 80 kg, so many patients are in the higher-risk group without knowing it. The BNF repeats the College's monitoring advice. It still expresses the maximum dose a different way, as 6.5 mg/kg per day of ideal body weight, so the two figures should not be confused.
Other drugs that damage the retina
| Drug | Used for | Effect on the eye | What to do |
|---|---|---|---|
| Hydroxychloroquine | Lupus, rheumatoid arthritis | Parafoveal RPE and photoreceptor loss, bull's eye maculopathy. Irreversible | Annual OCT and autofluorescence after 5 years, or after 1 year with risk factors |
| Chloroquine | Malaria, occasionally rheumatic disease | Same retinopathy, at lower doses and sooner. Also whorl-shaped corneal deposits (vortex keratopathy), which are harmless and reversible | Annual monitoring after 1 year |
| Tamoxifen | Breast cancer | Fine glistening crystalline deposits at the macula, with cyst-like cavities at the fovea on OCT. May not reverse | Report visual symptoms; stop only in agreement with the oncologist. Also raises the risk of hydroxychloroquine retinopathy |
| Vigabatrin | Infantile spasms, resistant focal epilepsy | Visual field defects in about one third of patients, usually persisting after the drug is stopped | Visual field test before treatment and every 6 months (BNF) |
Vigabatrin differs from the others because it damages the peripheral field, classically as symmetrical concentric constriction in both eyes, more marked on the nasal side, while central acuity stays normal. The patient does not notice until the loss is advanced, which is why testing is scheduled and not triggered by symptoms. Formal field testing is not possible in infants, which makes monitoring difficult in the group that most often needs the drug.
A bull's eye maculopathy is a pattern, not a diagnosis. Besides hydroxychloroquine and chloroquine it is seen in cone dystrophy and Stargardt disease, which are covered in the lesson on inherited retinal dystrophies.
Summary
- Central serous chorioretinopathy is a serous detachment of the macula caused by a congested, leaky choroid and a defect in the RPE.
- It mainly affects men of working age and its strongest association is corticosteroid use by any route.
- Symptoms are central blur, micropsia, metamorphopsia and a hyperopic shift; OCT shows clear subretinal fluid.
- Fluorescein angiography shows an ink blot or, less often, a smokestack leak.
- Most acute episodes resolve within a few months; chronic disease is treated with half-dose verteporfin photodynamic therapy, not eplerenone.
- Hydroxychloroquine binds melanin in the RPE and causes an irreversible parafoveal retinopathy ending in bull's eye maculopathy.
- RCOphth 2020: no baseline test, annual OCT and fundus autofluorescence after 5 years, or after 1 year with high dose, renal impairment, tamoxifen or chloroquine.
- The risk threshold for hydroxychloroquine is a dose above 5 mg/kg per day.
- Tamoxifen causes a crystalline maculopathy; vigabatrin causes persistent visual field defects in about a third of patients and needs field tests every 6 months.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.